[Clinicopathologic features of drug-induced vanishing bile duct syndrome]
- PMID: 28494557
- DOI: 10.3760/cma.j.issn.1007-3418.2017.04.019
[Clinicopathologic features of drug-induced vanishing bile duct syndrome]
Abstract
Vanishing bile duct syndrome (VBDS) manifests as progressive destruction and disappearance of the intrahepatic bile duct caused by various factors and cholestasis. VBDS associated with drug-induced liver injury (D-VBDS) is an important etiology of VBDS, and immune disorder or immune imbalance may be the main pathogenesis. According to its clinical symptoms, serological markers, and course of the disease, D-VBDS is classified into major form and minor form, and its clinical features are based on various pathomorphological findings. Its prognosis is associated various factors including regeneration of bile duct cells, number of bile duct injuries, level and range of bile duct injury, bile duct proliferation, and compensatory shunt of bile duct branches. This disease has various clinical outcomes; most patients have good prognosis after drug withdrawal, and some patients may experience cholestatic cirrhosis, liver failure, and even death. Due to the clinical manifestation and biochemical changes are similar to the primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), it need to identify by clinical physician.
胆管消失综合征(VBDS)是由多种因素引起的肝内部分胆管树持续进行性破坏和消失为病理形态学特征,以胆汁淤积为主要临床表现的疾病。其中药物性肝损伤相关的胆管消失综合征(D-VBDS)是VBDS的重要病因之一,免疫紊乱或者免疫失衡可能是主要的发病机制。D-VBDS依据临床症状、血清学指标及病程演变分主要形式及次要形式两种临床类型,其不同的临床症状及病情演变是以综合多样的病理形态学为基础;其预后转归与胆管细胞的再生情况、胆管损伤数量、胆管损伤级别、胆管损伤波及范围、细胆管增生以及其他胆管分支代偿分流等替代途径多种综合因素有关。该病的临床结局呈多样性,多数患者停药之后预后较好,少数则导致胆汁淤积性肝硬化、肝衰竭及死亡。由于其临床表现及生物化学指标改变与原发性胆汁性胆管炎、原发性硬化性胆管炎相类似,需要临床医生予以鉴别。.
Keywords: Drug induced; Pathogenetic mechanism; Pathology, clinical; Prognosis; Vanishing bile duct syndrome.
Similar articles
-
Meropenem-induced vanishing bile duct syndrome.Pharmacotherapy. 2010 Sep;30(9):953. doi: 10.1592/phco.30.9.953. Pharmacotherapy. 2010. PMID: 20812433
-
Vanishing bile duct syndrome in Hodgkin's lymphoma: A case report and literature review.World J Gastroenterol. 2017 Jan 14;23(2):366-372. doi: 10.3748/wjg.v23.i2.366. World J Gastroenterol. 2017. PMID: 28127210 Free PMC article. Review.
-
Pathophysiology and Diseases of the Proximal Pathways of the Biliary System.Arch Pathol Lab Med. 2015 Jul;139(7):858-66. doi: 10.5858/arpa.2014-0229-RA. Arch Pathol Lab Med. 2015. PMID: 26125426 Review.
-
Ursodeoxycholic acid treatment of vanishing bile duct syndromes.World J Gastroenterol. 2006 Jun 14;12(22):3487-95. doi: 10.3748/wjg.v12.i22.3487. World J Gastroenterol. 2006. PMID: 16773706 Free PMC article. Review.
-
Two-dimensional ultrasonography and CEUS of a case with primary biliary cholangitis and vanishing bile duct syndrome.J Clin Ultrasound. 2022 Nov;50(9):1368-1372. doi: 10.1002/jcu.23350. Epub 2022 Sep 23. J Clin Ultrasound. 2022. PMID: 36149806
Cited by
-
Primary biliary cholangitis associated with drug-induced liver injury and alcoholic liver fibrosis: A case report.Medicine (Baltimore). 2018 Sep;97(37):e12395. doi: 10.1097/MD.0000000000012395. Medicine (Baltimore). 2018. PMID: 30213010 Free PMC article.
-
Meta-Analysis of Antinuclear Antibodies in the Diagnosis of Antimitochondrial Antibody-Negative Primary Biliary Cholangitis.Gastroenterol Res Pract. 2019 Jun 10;2019:8959103. doi: 10.1155/2019/8959103. eCollection 2019. Gastroenterol Res Pract. 2019. PMID: 31281353 Free PMC article.
-
Histopathological Features Predicting Long-term Clinical Outcomes in Patients with Vanishing Bile Duct Syndrome.J Clin Transl Hepatol. 2023 Oct 28;11(5):1161-1169. doi: 10.14218/JCTH.2022.00039. Epub 2023 Apr 4. J Clin Transl Hepatol. 2023. PMID: 37577216 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical